MSKCC Oncologic Toxicity Management Symposium 2025

Include: 27 videos + 24 pdfs, size: 3.55 GB by Memorial Sloan Kettering Cancer Center

Overview

The 2025 Oncology Toxicity Management Symposium unites leading oncologists, researchers, and healthcare professionals to explore the latest breakthroughs in cancer treatment and toxicity management. With rapid advancements in oncology, this symposium serves as a critical platform for discussing emerging therapies, their clinical applications, and strategies to mitigate treatment-related adverse events, ultimately aiming to improve patient care and outcomes.

As oncology continues to evolve, new therapies are revolutionizing the landscape of cancer treatment. This symposium will provide a comprehensive, evidence-based approach to understanding next-generation treatments, their efficacy, and the challenges associated with their implementation in clinical practice.

Attendees will gain deep insights into the mechanisms, benefits, and risks of cutting-edge therapies, including:

• Radioligand Therapy – A novel approach that delivers targeted radiation to cancer cells, offering precise treatment with minimal damage to surrounding tissues. The session will focus on clinical applications, effectiveness, and strategies to manage radiation-related toxicity.
• Antibody Drug Conjugates (ADCs) – A breakthrough class of targeted cancer therapies designed to deliver highly potent chemotherapy directly to cancer cells. Experts will discuss the latest ADC developments, clinical benefits, and effective management of associated toxicities.
• CAR-T Cell Therapy – A groundbreaking immunotherapy that harnesses the body’s own immune system to fight cancer. This session will address treatment protocols and management of adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Bispecific Antibodies – A cutting-edge approach that redirects T-cells to attack tumor cells. Attendees will gain an understanding of the potential of Bispecific Antibodies, their clinical applications, and how to mitigate immune-related toxicities.
• Small Molecule Inhibitors (SMIs) – Targeted agents that block key pathways involved in cancer growth. This session will explore the role of SMIs in oncology, their therapeutic potential, and management of associated risks such as cardiovascular toxicity and metabolic disturbances.
• Immune Checkpoint Inhibitors (ICIs) – A revolutionary class of immunotherapies that enhance the body’s natural ability to fight cancer. Experts will discuss how ICIs are reshaping oncology, the challenges of immune-related adverse events (irAEs), and best practices for toxicity management.

Through expert-led presentations, panel discussions, and interactive Q&A sessions, attendees will deepen their understanding of novel therapies transforming oncology care, learn strategies to manage treatment-related toxicities, engage with thought leaders on cutting-edge research and clinical trials, and connect with peers to foster innovation in cancer treatment.

Target Audience

This symposium is an essential event for oncologists, hematologists, researchers, nurse practitioners, physician assistants, pharmacists, and all healthcare professionals involved in cancer care. Attendees will leave with actionable knowledge and practical tools to optimize patient outcomes and stay at the forefront of oncology advancements.

1. Describe the mechanism of action, indications, and clinical efficacy of Radioligand Therapy, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, CAR-T Cell Therapy, Small Molecule Inhibitors (SMIs), and Immune Checkpoint Inhibitors (ICIs).
2. Develop evidence-based strategies to identify, prevent, and manage treatment-related toxicities, such as cytokine release syndrome (CRS), neurotoxicity, immune-related adverse events (irAEs), and organ-specific toxicities.
3. Recognize the early signs of adverse reactions and implement effective interventions to reduce complications and improve patient safety.
4. Apply clinical case studies and expert insights to make informed, patient-centered decisions in oncology treatment planning.
5. Discuss how to balance treatment efficacy with toxicity management to optimize long-term patient outcomes.

Topics:

Friday, June 20, 2025

• 8:10AM – 8:55AM Enhancing the Selectivity of RLT for Future Treatments and Trials Michael J. Morris , MD
• 9:00AM – 9:15AM HER2-ADCs Eleni Stavrou, MD
• 9:15AM – 9:30AM TROP-2 ADCs Jie Chi, MD, Assistant Attending
• 9:30AM – 9:45AM NECTIN-4 ADCs Gopakumar Iyer, MD
• 9:45AM – 10:00AM Hematologic Malignancies and ADCs Nisha Joseph, MD
• 10:00AM – 10:15AM Management of Dermatological Adverse Events with ADCs Allison Gordon, MD
• 10:15AM – 10:30AM Antibody Drug Conjugates (ADCs) Panel Discussion/Q&A Neil Shah, MD (Moderator)
• 10:45AM – 11:00AM Bispecific Antibodies for Small Cell Cancers— DLL3 and Beyond Alissa Cooper, MD
• 11:15AM – 11:30AM Bispecific Antibodies for Leukemia and Lymphoma Suchita Sundaram, MD
• 11:30AM – 11:45AM Bispecific Antibodies for Multiple Myeloma Carlyn Tan, MD
• 11:45AM – 12:00PM Bispecific Antibodies Panel Discussion/Q&A Urvi Shah , MD
• 1:00PM – 1:15PM Immune Effector Cell (IEC) Toxicities in Solid Tumor Geoffrey Ku, MD
• 1:15PM – 1:30PM CAR-T for Myeloma Doris Hansen, MD
• 1:30PM – 1:45PM CAR-T for Lymphoma Gunjan Shah , MD, MS
• 1:45PM – 2:00PM CAR-T for Leukemia Mark B Geyer , MD
• 2:00PM – 2:15PM Managent of Graft vs. Host Disease and Other CAR-T Adverse Events Gagan Raju , MD, MD
• 2:15PM – 2:30PM Management of Neurotoxicity with Oncology Agents Bianca D. Santomasso, MD, PhD
• 2:30PM – 2:45PM CAR-T Cell Therapies Panel Discussion/Q&A David Faleck, MD (Moderator)
• 3:00PM – 3:15PM VEGF Tyrosine Kinase Inhibitors and HIF-2 Alpha Inhibitors Martin H Voss, MD
• 3:15PM – 3:30PM EGFR and ALK Inhibitors Isabel Preeshagul, MD
• 3:30PM – 4:00PM CDK4/6 and PI3K Inhibitors Serena Wong, MD
• 4:00PM – 4:30PM Management of Endocrine Adverse Events James Flory , MD
• 4:40PM – 4:55PM LAG-3 Inhibitors Michael Postow, MD
• 4:55PM – 5:10PM Management of Infusion Reactions from ICIs and Other Oncology Agents Autumn C Guyer, MD
• 5:10PM – 5:25PM Management of Gastrointestinal Immune-Related Adverse Events David Faleck, MD
• 5:25PM – 5:40PM Management of Cutaneous Immune-Related Adverse Events Alina Markova , MD
• 5:40PM – 5:55PM Novel Immune Checkpoint Inhibitors (ICIs) Panel Discussion/Q&A Steven Maron, MD,MSc (Moderator)